Completed PHASE1 INTERVENTIONAL 2-arm NCT02466347

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block

A Single-Dose, Randomized, Open-Label, Crossover, Pivotal, Comparative Bioavailability Study of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in Healthy Volunteers Without Charcoal Block

Sponsor: Intech Biopharm Ltd.

Conditions Asthma Chronic Obstructive Pulmonary Disease (COPD)

Interventions Fluticasone propionate Salmeterol (as xinafoate)

Updated 5 times since 2017 Last updated: Jul 25, 2016 Started: Jun 30, 2014 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02466347, this PHASE1 trial focuses on Asthma and Chronic Obstructive Pulmonary Disease (COPD) and remains completed. Sponsored by Intech Biopharm Ltd., it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Intech Biopharm Ltd.

Data source: Intech Biopharm Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Taipei City, Taiwan